Condition: Sickle Cell Disease · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in healthy participants and patients with sickle cell disease (SCD).
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| University of Alabama Birmingham | Birmingham, Alabama, United States | Recruiting |
| Quotient Sciences Sea View | Miami, Florida, United States | Completed |
| Boston Childrens Hospital | Boston, Massachusetts, United States | Recruiting |
| East Carolina University | Greenville, North Carolina, United States | Recruiting |
| Childrens Hospital Of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| Lifespan | Providence, Rhode Island, United States | Recruiting |
| UT Health Science Center | Houston, Texas, United States | Recruiting |
| Novartis Investigative Site | Ankara, Sihhiye-Altindag, Turkey (Türkiye) | Recruiting |
| Novartis Investigative Site | Adana, Yuregir, Turkey (Türkiye) | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06546670